A5073800403- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- COVID-19 Clinical Research Studies
- Herpesvirus Infections and Treatments
- Heavy Metal Exposure and Toxicity
- SARS-CoV-2 detection and testing
- Hepatitis B Virus Studies
- Animal Virus Infections Studies
- Gastric Cancer Management and Outcomes
- Respiratory viral infections research
- Trace Elements in Health
- Hepatitis C virus research
- Clostridium difficile and Clostridium perfringens research
- COVID-19 Impact on Reproduction
- Influenza Virus Research Studies
- Environmental Toxicology and Ecotoxicology
- Down syndrome and intellectual disability research
- Systemic Lupus Erythematosus Research
- Microscopic Colitis
- Bartonella species infections research
- Salmonella and Campylobacter epidemiology
- Colorectal Cancer Screening and Detection
- Bacterial Infections and Vaccines
- Liver Disease Diagnosis and Treatment
Kaiser Permanente
2021-2025
Frauenklinik Heidelberg
2025
National Center for Emerging and Zoonotic Infectious Diseases
2023
University of Pittsburgh
2023
University of Michigan–Ann Arbor
2023
Marshfield Clinic
2023
Texas A&M University
2023
Baylor Scott & White Health
2023
Centers for Disease Control and Prevention
2023
Vanderbilt University Medical Center
2023
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case–control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization or Delta. The large, diverse population included 26,683 SARS-CoV-2 test-positive cases variants determined by S gene target failure status (16% Delta 84% Omicron). two-dose VE at 14–90 days was 44.0% (95%...
To evaluate the effectiveness of mRNA-1273 vaccine against SARS-CoV-2 variants and assess its delta variant by time since vaccination.Test negative case-control study.Kaiser Permanente Southern California (KPSC), an integrated healthcare system.Adult KPSC members with a positive test sent for whole genome sequencing or from 1 March 2021 to 27 July 2021.Two dose one vaccination (Moderna covid-19 vaccine) ≥14 days before specimen collection versus no vaccination.Outcomes included infection...
In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months. Each season since 2004-05, CDC has estimated effectiveness of vaccine to prevent influenza-associated, medically attended acute respiratory illness (ARI). This report uses data from 2,319 children and adults enrolled in U.S. Influenza Vaccine Effectiveness (Flu VE) Network during December 2, 2013-January 23, 2014, estimate an interim adjusted preventing laboratory-confirmed...
Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against omicron BA.4/BA.5 compared with earlier subvariants. This test-negative case-control study evaluates mRNA-1273 vaccine effectiveness (VE) infection hospitalization The includes 30,809 positive 92,427 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE BA.1 is high wanes slowly, BA.2, BA.2.12.1, BA.4, BA.5 initially moderate to (61.0%-90.6% 14-30 days post...
The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study evaluate the effectiveness of in preventing hospitalization for (primary outcome) medically attended SARS-CoV-2 infection hospital death (secondary outcomes). Compared individuals who did not receive mRNA vaccination but received ≥2 doses any monovalent vaccine, relative (rVE) 70.3% (95% confidence interval, 64.0%-75.4%)....
Phase 3 trials found mRNA-1273 was highly effective in preventing COVID-19. We conducted a prospective cohort study at Kaiser Permanente Southern California (KPSC) to determine the real-world vaccine effectiveness (VE) of COVID-19 infection and severe disease.For this planned interim analysis, individuals aged ≥18 years receiving 2 doses ≥24 days apart (18/12/2020-31/03/2021) were 1:1 matched randomly selected unvaccinated by age, sex, race/ethnicity, with follow-up through 30/06/2021....
Abstract SARS-CoV-2 omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case-control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization or delta. The large, diverse population included 26,683 test-positive cases determined by spike gene status (16% delta, 84% omicron). 2-dose VE at 14-90 days was 44.0% (95% CI, 35.1–51.6%) but declined quickly. 3-dose 93.7% (92.2–94.9%) 86.0% (78.1–91.1%)...
Abstract Background In the United States, influenza activity during 2021–2022 season was modest and sufficient enough to estimate vaccine effectiveness (VE) for first time since beginning of coronavirus disease 2019 pandemic. We estimated VE against laboratory-confirmed outpatient acute illness caused by predominant A(H3N2) viruses. Methods Between October 2021 April 2022, research staff across 7 sites enrolled patients aged ≥6 months seeking care respiratory with cough. Using a...
Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any vaccine for >1 year. Assessment of long-term effectiveness bivalent vaccines against circulating is important inform the potential need vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 June 30, 2023), were matched 1:3...
Mammals are able to convert inorganic arsenic mono-, di-, and trimethylated metabolites. In previous studies we have shown that the trivalent organoarsenic compounds more toxic than their counterparts toxicity is associated with cellular uptake of arsenicals. present study, investigated cyto-/genotoxic effects arsenate [Asi(V)], arsenite [Asi(III)], monomethylarsonic acid [MMA(V)], monomethylarsonous [MMA(III)], dimethylarsinic [DMA(V)], dimethylarsinous [DMA(III)], trimethylarsine oxide...
Data on the effectiveness of 3-dose mRNA-1273 primary series are limited, particularly in comparison to 2 doses. Given suboptimal COVID-19 vaccine uptake among immunocompromised populations, it is important monitor fewer than recommended doses this population. We conducted a matched cohort study at Kaiser Permanente Southern California evaluate relative (rVE) vs preventing SARS-CoV-2 infection and severe outcomes individuals. included 21,942 recipients who were 1:1 with randomly selected...
Abstract Background Adults with inflammatory bowel disease (IBD) are at higher risk of herpes zoster (HZ) compared to the general population. In 2021, Advisory Committee on Immunization Practices recommended 2 doses recombinant vaccine (RZV) for prevention HZ and its complications in immunocompromised adults ≥19 years. this study, we evaluated effectiveness (VE) RZV flares ≥50 years IBD. Methods To evaluate VE, conducted a retrospective matched cohort analysis Kaiser Permanente Southern...
In an interim analysis, we evaluated vaccine effectiveness (VE) against herpes zoster (HZ) and postherpetic neuralgia (PHN) safety of recombinant (RZV) in adults aged ≥50 years with rheumatoid arthritis (RA). VE was assessed using a retrospective matched cohort analysis Kaiser Permanente Southern California members RA receiving 2 RZV doses (≥4 weeks apart) up to 1:3 RZV-unvaccinated individuals. Stratified Cox proportional hazards regression used estimate adjusted hazard ratios HZ PHN....
Background: Phase 3 trials found mRNA-1273 was highly effective in preventing COVID-19. We conducted a prospective cohort study at Kaiser Permanente Southern California (KPSC) to determine the real-world vaccine effectiveness (VE) of COVID-19 diagnosis and severe disease.Methods: For this planned interim analysis, individuals aged ≥18 years receiving 2 doses ≥24 days apart (12/18/2020-3/31/2021) were 1:1 matched with randomly selected unvaccinated on age, sex, race/ethnicity, follow-up...
Abstract Background Some vaccines elicit nonspecific immune responses that may protect against heterologous infections. We evaluated the association between recombinant adjuvanted zoster vaccine (RZV) and coronavirus disease 2019 (COVID-19) outcomes at Kaiser Permanente Southern California. Methods In a cohort design, adults aged ≥50 years who received ≥1 RZV dose before 1 March 2020 were matched 1:2 to unvaccinated individuals followed until 31 December 2020. Adjusted hazard ratios (aHRs)...
We conducted a prospective cohort study at Kaiser Permanente Southern California to the vaccine effectiveness (VE) of mRNA-1273 over time and during emergence Delta variant.The for this planned interim analysis consisted individuals aged ≥18 years receiving 2 doses through June 2021, matched 1:1 randomly selected unvaccinated by age, sex, race/ethnicity, with follow-up September 2021. Outcomes were SARS-CoV-2 infection, COVID-19 hospitalization hospital death. Cox proportional hazards models...
We estimated SARS-CoV-2 Delta- and Omicron-specific effectiveness of two three mRNA COVID-19 vaccine doses in adults against symptomatic illness US outpatient settings.
Background Adverse events following mRNA COVID-19 vaccines, including herpes zoster (HZ), have been reported. We conducted a cohort study to evaluate the association between vaccination and subsequent HZ at Kaiser Permanente Southern California (KPSC).Research design methods The vaccinated consisted of KPSC members who received their first dose vaccine (mRNA-1273 BNT162b2) during 12/2020–05/2021 were matched unvaccinated individuals on age sex. Incident cases occurring within 90 days...
We evaluated relative vaccine effectiveness (rVE) of 4- vs. 3-dose mRNA-1273 against SARS-CoV-2 infection, and COVID-19 hospitalization death in immunocompetent adults aged ≥50 years at Kaiser Permanente Southern California. included 178,492 individuals who received a fourth dose mRNA-1273, randomly selected recipients were matched to 4-dose by age, sex, race/ethnicity, third date. Adjusted rVE hospitalization, 25.9 % (23.5 %, 28.2 %), 67.3 (58.7 74.1 72.5 (-35.9 95.2 respectively. infection...
We evaluated the vaccine effectiveness (VE) of two doses recombinant zoster (RZV) against herpes (HZ) and postherpetic neuralgia (PHN) in Chinese adults at Kaiser Permanente Southern California (KPSC). KPSC members were identified based on self-reported ethnicity or preferred spoken/written language. Those aged ≥50 years who received RZV 4 weeks to ≤ 6 months apart matched 1:4 unvaccinated followed through June 2022; second accrued 6/1/2018-12/31/2020. estimated incidence adjusted hazard...